Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

94 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

NCT00631579

Hyperuricemia Leukemia Lymphoma

COMPLETED PHASE2

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

NCT00360438

Leukemia Lymphoma Tumor Lysis Syndrome

COMPLETED PHASE1/PHASE2

Elitek (Rasburicase) Immuno-Monitoring Study

NCT01097369

Tumor Lysis Syndrome

TERMINATED

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

NCT01200485

Leukemia Lymphoma

COMPLETED PHASE2

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

NCT02742090

Chronic Lymphocytic Leukemia

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, 2 arm, open-label study;

* Arm A: Patients previously treated with a uricolytic agent;
* Arm B: Patients not previously treated with a uricolytic agent.

Patients receive rasburicase for 5 days and begin chemotherapy 4-24 hours after the first dose of rasburicase. Patients are followed at 14 and 35 days, at 3 and 6 months and every 6 months thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors Hyperuricemia Tumor Lysis Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rasburicase (SR29142)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Meets one of the following risk criteria for tumor lysis syndrome (TLS):

A patient is at high risk for TLS if he/she presents with:
* Hyperuricemia of malignancy (plasma uric acid \> 7.5 mg/dL);
* A diagnosis of a very aggressive lymphoma/leukemia based on the Revised European-American Lymphoma (REAL) classification of lymphoma/leukemia;
* Acute myeloid leukemia (AML);
* Chronic myeloid leukemia (CML) in blast crisis; or
* High grade myelodysplastic syndrome (refractory anemia with excess blast, refractory anemia with excess blast in transformation, or chronic myelomonocytic leukemia) only if they have \> 10% bone marrow blast and are given aggressive treatment similar to AML

A patient is at potential risk for TLS if he/she presents with:
* A diagnosis of an aggressive lymphoma/leukemia based on the REAL classification of lymphoma/leukemia plus 1 or more of the following criteria:

* Lactate dehydrogenase (LDH) \> 2 x upper limit of normal (ULN)(IU/L)
* Stage III-IV disease
* Stage I-II disease with 1 lymph node/tumor \> 5 cm in diameter
2. Patients previously treated with a uricolytic agent or not at their first relapse or refractory disease
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-3. ECOG equivalent derived from Karnofsky performance scale 100-30 or Lansky performance score 100-30 (patients \< or = 16 years of age) may also be used.
4. Life expectancy \>3 months
5. Negative pregnancy test (females of child bearing potential) and use of effective contraceptive method (both males and females). A pregnancy test may be performed on serum or urine human chorionic gonadotropin (HCG).
6. Signed written informed consent

Exclusion Criteria

1. History of established diagnosis of asthma or severe life-threatening atopic allergy
2. Hypersensitivity to uricases or any of the excipients
3. Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or history of hemolysis indicative of G6PD deficiency
4. Pregnant or lactating
5. Concomitant treatment with any investigational drug
6. Planned treatment with rituximab
7. Receipt of rituximab within the 12 month period prior to study entry
8. Unwilling or unable to comply with the requirements of the protocol

Eligible Sex

ALL

Accepts Healthy Volunteers

No